Cholinergic control of striatal neurons to modulate L‐dopa‐induced dyskinesias.

L‐dopa induced dyskinesias (LIDs) are a disabling motor complication of L‐dopa therapy for Parkinson's disease (PD) management. Treatment options remain limited and the underlying network mechanisms remain unclear due to a complex pathophysiology. What is well‐known, however, is that aberrant striatal signaling plays a key role in LIDs development. Here, we discuss the specific contribution of striatal cholinergic interneurons (ChIs) and GABAergic medium spiny projection neurons (MSNs) with a particular focus on how cholinergic signaling may integrate multiple striatal systems to modulate LIDs expression. Enhanced ChI transmission, altered MSN activity and the associated abnormal downstream signaling responses that arise with nigrostriatal damage are well known to contribute to LIDs development. In fact, enhancing M4 muscarinic receptor activity, a receptor favorably expressed on D1 dopamine receptor‐expressing MSNs dampens their activity to attenuate LIDs. Likewise, ChI activation via thalamostriatal neurons is shown to interrupt cortical signaling to enhance D2 dopamine receptor‐expressing MSN activity via M1 muscarinic receptors, which may interrupt ongoing motor activity. Notably, numerous preclinical studies also show that reducing nicotinic cholinergic receptor activity decreases LIDs. Taken together, these studies indicate the importance of cholinergic control of striatal neuronal activity and point to muscarinic and nicotinic receptors as significant pharmacological targets for alleviating LIDs in PD patients. Striatal cholinergic transmission may play a significant role in modulating L‐dopa‐induced dyskinesias. In this review, we discuss how activation of mAChRs may modulate MSN excitability (A, B) to reduce their occurrence. We also allude to the possibility that dampening the activity of nAChRs localized on GABAergic interneurons (C) may lessen L‐dopa‐induced dyskinesias. [ABSTRACT FROM AUTHOR]